Serum Gal-9 levels were positively correlated with NAFLD severity shown by sonography and serum levels of sTIM-3, FABP1, and FABP4, respectively, in RA patients. This evidence concerns the gene LGALS9 and metabolic dysfunction-associated steatotic liver disease.